Chieko Ishiguro

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 16

Top Topics

Respiratory Syndrome Coronavirus

Epidermal Growth Factor Receptor

Drug Administration

Top Venues

Open forum infectious diseases

Pharmacoepidemiology and drug safety

Therapeutic innovation & regulatory science

Human vaccines & immunotherapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Wataru Mimura, Chieko Ishiguro, Megumi Maeda, Fumiko Murata, Haruhisa Fukuda
Association between mRNA COVID-19 vaccine boosters and mortality in Japan: The VENUS study. Human vaccines & immunotherapeutics 20 (1) (2024)
Wataru Mimura, Chieko Ishiguro, Megumi Maeda, Fumiko Murata, Haruhisa Fukuda
Association between mRNA COVID-19 vaccine boosters and mortality in Japan: The VENUS study. Human vaccines & immunotherapeutics 20 (1) (2024)
Wataru Mimura, Chieko Ishiguro, Megumi Maeda, Fumiko Murata, Haruhisa Fukuda
Association between mRNA COVID-19 vaccine boosters and mortality in Japan: The VENUS study. Human vaccines & immunotherapeutics 20 (1) (2024)
Chieko Ishiguro, Wataru Mimura, Junko Terada, Nobuaki Matsunaga, Hironori Ishiwari, Hiroyuki Hoshimoto, Kengo Miyo, Norio Ohmagari
Development and validation of claims-based algorithms for identifying hospitalized patients with COVID-19 and their severity in 2020 and 2021. Journal of epidemiology (2024)
Chieko Ishiguro, Wataru Mimura, Yukari Uemura, Megumi Maeda, Fumiko Murata, Haruhisa Fukuda
Multiregional Population-Based Cohort Study for Evaluation of the Association Between Herpes Zoster and mRNA Vaccinations for Severe Acute Respiratory Syndrome Coronavirus-2: The VENUS Study. Open forum infectious diseases 10 (7) (2023)
Wataru Mimura, Chieko Ishiguro, Junko Terada-Hirashima, Nobuaki Matsunaga, Megumi Maeda, Fumiko Murata, Haruhisa Fukuda
Bivalent Vaccine Effectiveness Among Adults Aged ≥65 Years During the BA.5-Predominant Period in Japan: The VENUS Study. Open forum infectious diseases 10 (10) (2023)
Wataru Mimura, Chieko Ishiguro, Junko Terada-Hirashima, Nobuaki Matsunaga, Shuntaro Sato, Yurika Kawazoe, Megumi Maeda, Fumiko Murata, Haruhisa Fukuda
Effectiveness of BNT162b2 against infection, symptomatic infection, and hospitalization among older adults aged ≥65 years during the Delta variant predominance in Japan: The VENUS Study. Journal of epidemiology (2023)
Wataru Mimura, Chieko Ishiguro, Megumi Maeda, Fumiko Murata, Haruhisa Fukuda
Effectiveness of a Third Dose of COVID-19 mRNA Vaccine During the Omicron BA.1- and BA.2-Predominant Periods in Japan: The VENUS Study. Open forum infectious diseases 9 (12) (2022)
Wataru Mimura, Chieko Ishiguro, Megumi Maeda, Fumiko Murata, Haruhisa Fukuda
Effectiveness of a Third Dose of COVID-19 mRNA Vaccine During the Omicron BA.1- and BA.2-Predominant Periods in Japan: The VENUS Study. Open forum infectious diseases 9 (12) (2022)
Mei Kohama, Takahiro Nonaka, Yoshiaki Uyama, Chieko Ishiguro
Descriptive Analysis for the Trend of Pharmacovigilance Planning in Risk Management Plans on New Drugs Approved During 2016-2019. Therapeutic innovation & regulatory science (2022)
Tomoaki Hasegawa, Sono Sawada, Chieko Ishiguro, Takashi Ando, Kanae Kobayashi, Noriyuki Komiyama, Toyotaka Iguchi, Takahiro Nonaka, Yoshiaki Uyama
Assessing the Risk of Decrease in Kidney Function in Patients Prescribed Direct-Acting Antivirals for Hepatitis C Utilizing the MID-NET ® Medical Information Database Network in Japan. Therapeutic innovation & regulatory science 56 (4) (2022)
Mei Kohama, Takahiro Nonaka, Yoshiaki Uyama, Chieko Ishiguro
Correction: Descriptive Analysis for the Trend of Pharmacovigilance Planning in Risk Management Plans on New Drugs Approved During 2016-2019. Therapeutic innovation & regulatory science (2022)
Maki Komamine, Kazuhiro Kajiyama, Chieko Ishiguro, Yoshiaki Uyama
Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study. Pharmacoepidemiology and drug safety 28 (9) (2019)
Kaori Yamada, Maori Itoh, Yoshiaki Fujimura, Michio Kimura, Koichiro Murata, Naoki Nakashima, Masaharu Nakayama, Kazuhiko Ohe, Takao Orii, Eizaburo Sueoka, Takahiro Suzuki, Hideto Yokoi, Chieko Ishiguro, Yoshiaki Uyama, null null
The utilization and challenges of Japan's MID-NET® medical information database network in postmarketing drug safety assessments: A summary of pilot pharmacoepidemiological studies. Pharmacoepidemiology and drug safety 28 (5) (2019)
Ko Watanabe, Masayasu Murakami, Koichi Masuyama, Chieko Ishiguro, Tsutomu Matsuda
The association between concerns toward adverse reactions during pre-approval drug reviews and the post-approval addition of clinically significant adverse reactions to package inserts: A retrospective analysis of pre-approval drug review reports and safety updates. Pharmacoepidemiology and drug safety 27 (11) (2018)
Chieko Ishiguro, Takashi Misu, Eiko Iwasa, Tadashi Izawa
Analysis of safety-related regulatory actions by Japan's pharmaceutical regulatory agency. Pharmacoepidemiology and drug safety 26 (11) (2017)